Utility of Serum Biomarker Indices for Staging of Hepatic Fibrosis Before and After Venesection in Patients With Hemochromatosis Caused by Variants in HFE.

MLA

Chin, Justin, et al. “Utility of Serum Biomarker Indices for Staging of Hepatic Fibrosis Before and After Venesection in Patients With Hemochromatosis Caused by Variants in HFE.” Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association, vol. 19, no. 7, July 2021, p. 1459. EBSCOhost, https://doi.org/10.1016/j.cgh.2020.07.052.

APA

Chin, J., Powell, L. W., Ramm, L. E., Hartel, G. F., Olynyk, J. K., & Ramm, G. A. (2021). Utility of Serum Biomarker Indices for Staging of Hepatic Fibrosis Before and After Venesection in Patients With Hemochromatosis Caused by Variants in HFE. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association, 19(7), 1459. https://doi.org/10.1016/j.cgh.2020.07.052

Chicago

Chin, Justin, Lawrie W Powell, Louise E Ramm, Gunter F Hartel, John K Olynyk, and Grant A Ramm. 2021. “Utility of Serum Biomarker Indices for Staging of Hepatic Fibrosis Before and After Venesection in Patients With Hemochromatosis Caused by Variants in HFE.” Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association 19 (7): 1459. doi:10.1016/j.cgh.2020.07.052.